Document:

EX-10.6

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 

Exhibit 10.6 

***CONFIDENTIAL TREATMENT REQUESTED*** 

Note: Confidential treatment requested with respect to certain portions hereof denoted with 

“***” 
 December 17,
2018 
 AMENDED AND RESTATED SUBLICENSE AGREEMENT 

BETWEEN 
 MAYNE PHARMA
INTERNATIONAL PTY LTD 
 & 

HEDGEPATH PHARMACEUTICALS, INC. 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 AMENDED AND RESTATED SUBLICENSE AGREEMENT 

THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (this “Agreement”) is entered into effective as of December 17, 2018 by
and between MAYNE PHARMA INTERNATIONAL PTY LTD, ABN 88 007 870 984, an Australian body corporate having an address at 1538 Main North Road, Salisbury South, SA 5106, Australia (“Mayne Pharma”), and HEDGEPATH PHARMACEUTICALS, INC., a
company incorporated in Delaware having an address at 324 South Hyde Park Avenue #350, Tampa, Florida, 33606, United States (“HPPI”) with respect to the following: 

RECITALS 
 WHEREAS,
valuable inventions entitled “New Angiogenesis Inhibitors” (JHU Ref No C04494; hereinafter referred to as the “ANGIOGENESIS PATENT”), and “New uses for old drugs: Identification of Hedgehog Pathway Antagonists
previously tested in Humans” (JHU Ref No C04820; hereinafter referred to as the “HEDGEHOG PATENT”) have heretofore been developed during the course of research conducted by Drs Jun Liu, Curtis Chung, David Sullivan, Schrindar
Bhat, Jin Xu and Philip Beachy (all hereinafter “INVENTORS”); 
 WHEREAS, THE JOHNS HOPKINS UNIVERSITY, a Maryland
corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (“JHU”), has acquired through assignment all rights, title and interest, with the exception of certain retained rights by the United States
Government, in said valuable inventions; 
 WHEREAS, JHU has granted to Accelas Holdings, a BVI corporation having an address at Rm
1228,12/F, One Grand Tower, 639 Nathan Road, Kowloon, Hong Kong (“ACCELAS”) an exclusive license to commercially develop, manufacture, use and distribute products and processes based upon or embodying said valuable inventions
throughout the world under an exclusive license agreement effective on 14 December 2009, as varied by a first amendment effective on 22 May 2012 and a second amendment effective on 23 January 2014 (hereinafter referred to as the
“HEAD LICENSE”); 
 WHEREAS, Mayne Pharma obtained from Accelas a sublicense effective August 26, 2015 to commercially
develop, manufacture, use and distribute products and processes based upon or embodying said valuable inventions (hereinafter referred to as the “ACCELAS SUBLICENSE”); 

WHEREAS, HPPI and Mayne Pharma are parties to that certain Sublicense Agreement, dated as of August 31, 2015, under which HPPI obtained
from Mayne Pharma a sub-sublicense to commercially develop, manufacture, use and distribute products and processes based upon or embodying said valuable inventions in the United States of America, including
all commonwealths, territories and possessions thereof, on the terms and conditions set forth herein (hereinafter referred to as the “ORIGINAL AGREEMENT”); 

  
 Page 1 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 WHEREAS, HPPI and Mayne Pharma Ventures Pty Ltd ACN 168 896 357 (“MPV”), an
affiliate of Mayne Pharma, are entering into that certain Third Amended and Restated Supply and License Agreement dated as of even date herewith under which MPV agrees to supply HPPI with SUBA-Itraconazole hard capsules and provide a license to
certain intellectual property rights (hereinafter referred to as the “THIRD SLA”); and 
 WHEREAS, pursuant to that certain
Agreement, dated as of even date herewith, by and among, HPPI, MPV and Mayne Pharma, the parties hereto desire to amend and restate the ORIGINAL AGREEMENT to effect certain amendments, upon the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the premises and the mutual promises and covenants contained in this Agreement, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: 
 ARTICLE 1

 DEFINITIONS 
 All
references to particular Exhibits, Articles or Paragraphs shall mean the Exhibits to, and Paragraphs and Articles of, this Agreement, unless otherwise specified. For the purposes of this Agreement and the Exhibits hereto, the following words and
phrases shall have the following meanings: 
 1.1 “AFFILIATED COMPANY” as used herein in either singular or plural
shall mean any corporation, company, partnership, joint venture or other entity, which controls, is controlled by or is under common control with HPPI. For purposes of this Paragraph 1.1, control shall mean the direct or indirect ownership of at
least fifty- percent (50%). 
 1.1A “BCCNS FIELD” shall mean the treatment of human patients with Basal Cell
Carcinoma Nevus (Gorlin) Syndrome via oral administration. 
 1.2 “EFFECTIVE DATE” of this License Agreement shall
mean August 31, 2015. 
 1.3 “EXCLUSIVE LICENSE” shall mean a grant by Mayne Pharma to HPPI of its entire right
and interest as a licensee in the PATENT RIGHTS subject to rights retained by the United States Government, if any, in accordance with the Bayh-Dole Act of 1980 (established by P.L. 96-517 and amended by P.L. 98-620, codified at 35 USC § 200 et. seq. and implemented according to 37 CFR Part 401), and subject to the retained right of JHU under the Head License to make, have made, provide and use for its and The Johns
Hopkins Health Systems’ purposes LICENSED PRODUCT(S) and LICENSED SERVICE(S), including the ability to distribute any biological material disclosed and/or claimed in PATENT RIGHTS for nonprofit academic research use to non-commercial entities as is customary in the scientific community. 
 1.3A “FIRST
COMMERCIAL SALE” shall mean the first day of the calendar quarter that occurs after the first sale for use or consumption by the general public of a LICENSED PRODUCT in the LICENSED FIELD in the TERRITORY after all required marketing and
pricing approvals have been granted by the US Food and Drug Administration (“FDA”). 

  
 Page 2 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 1.4 “LICENSED FIELD” shall mean (i) for the ANGIOGENESIS PATENT:
itraconazole racemic mixture, for the treatment of human patients with any of the LICENSED INDICATIONS via oral administration under the PATENT RIGHTS (and specifically excluding TOPICAL USE); and (ii) for the HEDGEHOG PATENT: SYSTEMIC USE and
OCULAR USE of the racemic mixture of itraconazole for the treatment of human patients with any of the LICENSED INDICATIONS via oral administration. The LICENSED FIELD excludes the BCCNS FIELD and any fields not expressly listed above. ***.
 
 1.4A “LICENSED INDICATIONS” shall mean the following to the extent they are oncology and age-related macular degeneration indications (i) any prostate cancer, prostatic intraepithelial neoplasia (IEN) and benign prostatic hyperplasia, (ii) any lung cancer and atypical adenomatous
hyperplasia and (iii) familial adenomatous polyposis, colorectal polyps and Barett’s esophagus. The LICENSED INDICATIONS exclude the BCCNS FIELD and any indications not expressly listed above. 

1.5 “LICENSED PRODUCT(S)” as used herein in either singular or plural shall mean any process or method, material,
compositions, drug, or other product, the manufacture, use or sale of which would constitute, but for the license granted to HPPI pursuant to this Agreement, an infringement of a claim of PATENT RIGHTS (infringement shall include, but is not limited
to, direct, contributory, or inducement to infringe). 
 1.6 “LICENSED SERVICE(S)” as used herein in either singular
or plural shall mean the performance on behalf of a third party of any method or the manufacture of any product or the use of any product or composition which would constitute, but for the license granted to HPPI pursuant to this Agreement, an
infringement of a claim of the PATENT RIGHTS, (infringement shall include, but not be limited to, direct, contributory or inducement to infringe). 

1.7 “NET SALES” shall mean ***. 

1.8 “NET SERVICE REVENUES” shall mean ***. 

1.9 “PATENT RIGHTS” shall mean (i) US Provisional Application No 60/583,076 (JHU Ref No C04494) entitled “New
Angiogenesis Inhibitors”, subsequently filed as PCT/US05/23015 on June 27, 2005 (hereinafter referred to as “the ANGIOGENESIS PATENT”); and (ii) US patent No 8,653,083 entitled “Hedgehog Pathway Antagonists to Treat
Disease”, filed on August 22, 2005, and subsequently filed as PCT/US2006/32952 on August 22, 2006 (hereinafter referred to as “the HEDGEHOG PATENT”); and (iii) the inventions disclosed and claimed therein, and all
continuations, divisions and reissued based thereof, and any patents issuing, granted or registered therefrom. HPPI acknowledges and agrees that PATENT RIGHTS do not include ***. 

1.10 “SUBLICENSEE” shall mean any person or entity to which LICENSEE has granted a sublicense with the approval of
Mayne Pharma and JHU under Paragraph 2.2 of this Agreement. 

  
 Page 3 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 1.11 Not used. 

1.12 “OCULAR USE” shall mean application to the membranes, cornea or conjunctiva of the eye. 

1.13 “SYSTEMIC USE” shall mean internal application throughout the whole body and not confined to a specific localized
external area, including ingested or injected formulations of drugs, but excluding intradermal and subcutaneous injected formulations of drugs designed to locally treat external areas of the body and having a predominately local effect. 

1.14 “TOPICAL USE” shall mean application to an external area of the body and affecting mostly the area to which it is
applied, including intradermal and subcutaneous injection designed to locally treat such external area, including but not limited to the skin, ear and accessible mucous membranes including but not limited to those of the mouth, vagina and anus.
TOPICAL USE shall comprise of drug formulations and delivery mechanisms including but not limited to lotions, creams, ointments, gels, powders (talc), patches, nanoparticles, microneedles and solutions (liquids) but shall exclude systemic uses, such
as ingested or injected formulations of drugs. For the purpose of this agreement, TOPICAL USE shall specifically exclude OCULAR USE. 

1.15 Not used. 

1.16 “TERRITORY” shall mean the United States of America, including all commonwealths, territories and possessions
thereof. 
 1.17 “THIRD PARTY” shall mean any entity other than HPPI or any SUBLICENSEE. 

ARTICLE 2 
 LICENSE GRANT

 2.1 Grant. Subject to the terms and conditions of this Agreement, Mayne Pharma hereby grants to HPPI an EXCLUSIVE
LICENSE to make, have made, use, import, offer for sale and sell the LICENSED PRODUCT(S) and to provide the LICENSED SERVICE(S) in the TERRITORY under the PATENT RIGHTS in the LICENSED FIELD.  

2.2 No right of Sublicense. HPPI may not sublicense to others (including any AFFILIATED COMPANY) under this Agreement, except
with prior written consent of Mayne Pharma and JHU, which each may withhold or grant subject to conditions, in its discretion. 
 2.3
Government Rights. The United States Government may have acquired a nonexclusive, nontransferable, irrevocable, paid-up license to practice or have practiced for or on behalf of the United
States the inventions described in PATENT RIGHTS throughout the world. The rights granted herein are additionally subject to: (i) the requirement that any LICENSED PRODUCT(S) produced for use or sale within the United States shall be
substantially manufactured in the United States (unless a waiver under 35 USC § 204 or equivalent is granted 

  
 Page 4 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 
by the appropriate United States government agency), (ii) the right of the United States government to require JHU, or its licensees, including HPPI, to grant sublicenses to responsible
applicants on reasonable terms when necessary to fulfill health or safety needs, and, (iii) other rights acquired by the United States government under the laws and regulations applicable to the grant/contract award under which the inventions
were made. HPPI will reimburse to Mayne Pharma all costs and expenses reasonably incurred in connection with an application for a waiver under 35 USC § 204 or equivalent by the appropriate United States government agency to the extent it
relates to the LICENSED FIELD, within *** of the receipt of an invoice from Mayne Pharma and reasonable evidence of payment. 

ARTICLE 3 
 FEES,
ROYALTIES, PAYMENTS 
 3.1 License Fee. HPPI shall pay to Mayne Pharma within thirty (30) days of the EFFECTIVE DATE
of this Agreement a license fee as set forth in Exhibit A. The license fee is nonrefundable and shall not be credited against royalties or other fees. 

3.2 Minimum Annual Royalties. HPPI shall pay to Mayne Pharma minimum annual royalties as set forth in Exhibit A. These
minimum annual royalties shall be due within *** after the FIRST COMMERCIAL SALE of a LICENSED PRODUCT occurs. Running royalties accrued under Paragraph 3.3 and paid to Mayne Pharma during the *** of the FIRST COMMERCIAL SALE shall be
credited against the minimum annual royalties due on that date. Minimum annual royalties cease to be payable on the earlier of (i) the expiry or lapse of all PATENT RIGHTS that have been granted, issued or registered in the TERRITORY; or
(ii) there is no longer a marketing authorization in place for sale of a LICENSED PRODUCT in the LICENSED FIELD in the TERRITORY. 

3.3 Running Royalties. HPPI shall pay to Mayne Pharma a running royalty as set forth in Exhibit A, for each LICENSED
PRODUCT(S) sold, and for each LICENSED SERVICE(S) provided, by HPPI and any SUBLICENSEE(S), based on NET SALES and NET SERVICE REVENUES for the term of this Agreement. Such payments shall be made quarterly from the FIRST COMMERCIAL SALE of a
LICENSED PRODUCT occurs. 
 3.4 Not used.  

3.5 Milestone Payments. HPPI shall pay to Mayne Pharma milestone payments as set forth in Exhibit A, upon the occurrence
of the milestone events described therein whether achieved by (a) HPPI or any SUBLICENSEE with respect to a LICENSED PRODUCT in the LICENSED FIELD, or (b) Mayne Pharma or any of its sublicensees with respect to a LICENSED PRODUCT in the
BCCNS FIELD. HPPI shall provide written notice to Mayne Pharma within *** of achievement of the milestones numbered 1, 2 and 3 in Exhibit A in the LICENSED FIELD. These milestone payments shall be due within *** following
receipt by HPPI of an invoice therefor. 

  
 Page 5 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 3.6 Patent Reimbursement. In accordance with Paragraph 4.1 below, HPPI
will reimburse Mayne Pharma, within *** of the receipt of an invoice from Mayne Pharma and reasonable evidence of payment, for all costs associated with the preparation, filing, maintenance, and prosecution of the PATENT RIGHTS in the
TERRITORY incurred by Accelas subsequent to the EFFECTIVE DATE of the Accelas Sublicense (which costs are to be reimbursed by Mayne Pharma to Accelas under the Accelas Sublicence). 

3.7 Payment. All payments under this Agreement (including payments under this Article 3 and Paragraph 4.1) shall be
payable within *** after HPPI receives an invoice or at any time specified for payment in this Agreement, whichever is the later. Amounts are payable in USD, and where necessary, converted at an average daily exchange rate to buy USD for the
applicable calendar quarter to which that payment relates, as published in the Wall Street Journal. 
 3.8 Payment Information.
All check payments from HPPI to Mayne Pharma shall be sent to such address which Mayne Pharma may designate in writing from time to time. Checks are to be made payable to “Mayne Pharma”. Wire transfers may be made to the account which
Mayne Pharma may designate in writing from time to time. HPPI shall be responsible for any and all costs associated with wire transfers. 

3.9 Late Payments. In the event that any payment due hereunder is not made when due, the payment shall accrue interest beginning
on the *** following the due date thereof, calculated at the annual rate of the sum of (a) *** plus (b) ***, provided however, that in no event shall said annual interest rate exceed the maximum legal interest rate for
corporations. Each such payment when made shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of any party to seek any other remedy, legal or equitable, to which
it may be entitled because of the delinquency of any payment including, but not limited to termination of this Agreement as set forth in Paragraph 9.2. 

3.10 Withholding tax. 

(a) If any payment or deliverable under this Agreement is subject to any tax, duties, levies, charges, fees or other imposts of any kind
(“Taxes”) which HPPI is required at law to withhold, then HPPI will withhold that amount and deduct it from the payments required to be made to Mayne Pharma under this Agreement. HPPI will promptly provide to Mayne Pharma
certificates or any other form of documentary evidence issued by any authority regarding the payment of any such Taxes. HPPI will sign all lawful documents as reasonably requested by Mayne Pharma as is necessary to able Mayne Pharma to take
advantage of any applicable legal provision or any double taxation treaties that would result in limiting the amount of any such Taxes. 

(b) Where any sum due to be paid to Mayne Pharma hereunder is subject to any withholding or similar tax, HPPI shall use its commercially
reasonable efforts to do all such acts and things and to sign all such documents as will enable it to take advantage of any applicable double taxation agreement or treaty. In the event there is no applicable double taxation agreement or treaty, or
if an applicable double taxation agreement or treaty reduces but does not eliminate such withholding or similar tax, HPPI shall pay such withholding or similar tax to the appropriate government authority, deduct the amount paid from the amount paid
to Mayne Pharma and secure and send to Mayne Pharma the best available evidence of such payment. 

  
 Page 6 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 (c) For any period during the term of this Agreement where there is no applicable double
taxation agreement or treaty, to the extent that Mayne Pharma, acting reasonably, is not able to obtain the benefit of any amounts withheld or deducted by HPPI under this Agreement, then Mayne Pharma shall give notice of this to HPPI and HPPI must
pay Mayne Pharma such additional amounts as necessary to ensure Mayne Pharma receives, when due, a net amount (after deduction or withholding of Taxes in respect of such additional amounts) equal to the full amount which Mayne Pharma would have
received if no deduction or withholding had been made. 
 ARTICLE 4 

PATENT PROSECUTION, MAINTENANCE, & INFRINGEMENT 

4.1 Prosecution & Maintenance. 

4.1.1 Title to all PATENT RIGHTS pursuant to this Agreement shall reside in JHU. 

4.1.2 The parties acknowledge that, under the Head License, JHU shall take primary responsibility for the prosecution and maintenance of all
PATENT RIGHTS in the TERRITORY. JHU shall have primary responsibility for the PATENT RIGHTS prosecuted and maintained in any jurisdiction in the TERRITORY, and at HPPI’s expense, shall file, prosecute and maintain all such patents and patent
applications that, subject to the terms and conditions of this Agreement, HPPI has obtained a license hereunder. Notwithstanding the forgoing, JHU shall have full and complete control over all patent prosecution matters in connection therewith under
the PATENT RIGHTS in the TERRITORY, provided however, that Mayne Pharma shall (a) timely provide to HPPI copies of non-confidential official actions and written correspondence with the USPTO regarding the
PATENT RIGHTS in the TERRITORY, and (b) consult with HPPI and allow HPPI an opportunity to comment, which comments Mayne Pharma will consider and as appropriate, pass onto JHU. 

4.1.3 Provided Mayne Pharma has provided HPPI with at least *** advance written notice of any filing or response deadline
or fee due date, by written notification to Mayne Pharma at least *** of any filing or response deadline, or fee due date (or where Mayne Pharma has not provided sufficient advance notice, such shorter period such that HPPI has at least
*** to consider its election), HPPI may elect not to have a patent application filed or not to pay expenses associated with prosecuting or maintaining any patent application or patent comprising the PATENT RIGHTS, provided that HPPI pays for
all costs incurred up to receipt of such notification. Failure to provide such notification can be considered to be HPPI’s authorization to proceed at HPPI’s expense. Upon such notification, on behalf of Mayne Pharma, JHU may file,
prosecute, and/or maintain such patent applications or patent at its own expense and for its own benefit and any rights or license granted hereunder held by HPPI or any SUBLICENSEE(S) relating to the PATENT RIGHTS which comprise the subject of such
patent applications or patent and/or apply to the TERRITORY, shall terminate.  

  
 Page 7 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 4.2 Notification. Each party will notify the other promptly in writing
when any infringement by another is uncovered or suspected. 
 4.3 Infringement. 

(a) Mayne Pharma shall have the first right to enforce any patent within PATENT RIGHTS against any infringement or alleged infringement
thereof within LICENSED FIELD in the TERRITORY. Subject to Paragraph 4.5A, *** will pay all reasonable costs and expenses (including reasonable attorney fees for litigation and opinion) incurred by *** in connection with such
enforcement (Enforcement Costs). Before Mayne Pharma commences an action with respect to any infringement of such patents, HPPI acknowledges and agrees that Mayne Pharma shall give careful consideration to the views of JHU and to potential
effects on the public interest in making its decision whether or not to sue. HPPI acknowledges and agrees that no settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the prior written consent of
JHU, which consent shall not be unreasonably withheld. This right to sue for infringement shall not be used in an arbitrary or capricious manner. HPPI shall reasonably cooperate in any such litigation at *** expense, including in accordance
with Paragraph 4.6. Should HPPI seek the first right to enforce any patent within PATENT RIGHTS against any infringement or alleged infringement thereof within LICENSED FIELD in the TERRITORY, then it shall notify Mayne Pharma who will seek the
consent of JHU (which consent HPPI acknowledges may be withheld or granted subject to conditions by JHU acting in its discretion). 
 (b) If
HPPI elects not to pay Enforcement Costs in respect of a particular infringement in the TERRITORY, then it shall so notify Mayne Pharma in writing within *** of receiving notice that an infringement exists, and Mayne Pharma may, in its sole
judgment and at its own expense, take steps to enforce any patent and control, settle, and defend such suit in a manner consistent with the terms and provisions hereof, and recover, for its own account, any damages, awards or settlements resulting
therefrom, or may allow JHU to do so. 
 4.4 Patent Invalidity Suit. Mayne Pharma shall have the first right to defend any
declaratory judgment action or similar proceeding (including post grant review before any patent office or inter partes review before the Patent Trial and Appeal Board of the USPTO) alleging invalidity of any of the PATENT RIGHTS within
LICENSED FIELD in the TERRITORY. Subject to Paragraph 4.5A, *** will pay all reasonable costs and expenses (including reasonable attorney fees for litigation and opinion) incurred by *** in connection with such defense. HPPI
acknowledges and agrees that no settlement, consent judgment or other voluntary final disposition of the suit may be entered into without the prior written consent of JHU, which consent shall not be unreasonably withheld. Should HPPI seek the first
right to defend any declaratory judgment action or similar proceeding (including post grant review before any patent office or inter partes review before the Patent Trial and Appeal Board of the USPTO) alleging invalidity of any of the PATENT
RIGHTS within LICENSED FIELD in the TERRITORY, then it shall notify Mayne Pharma who will seek the consent of JHU (which consent HPPI acknowledges may be withheld or granted subject to conditions by JHU acting in its discretion). 

  
 Page 8 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 4.5 Recovery. Any recovery by Mayne Pharma under Paragraph 4.3 shall be paid:

 (a) first to *** to reimburse its Enforcement Costs; and 

(b) following *** recovery of its Enforcement Costs, the Parties shall share equally in the recovery. If the Enforcement Costs exceed
the recovery, then *** shall be credited against royalties payable by HPPI to Mayne Pharma hereunder in connection with sales of LICENSED PRODUCT covered in the PATENT RIGHTS which are the subject of the infringement suit in the TERRITORY,
provided, however, that any such credit under this Paragraph shall not exceed *** of the royalties otherwise payable to Mayne Pharma with regard to sales in the TERRITORY in any one calendar year, with any excess credit being carried forward
to future calendar years. 
 4.5A Joint litigation committee. Mayne Pharma shall manage the conduct of any enforcement of any
patent within PATENT RIGHTS against any infringement or alleged infringement thereof within LICENSED FIELD in the TERRITORY or defense of any declaration judgment or similar proceeding (including post grant review before any patent office or
inter partes review before the Patent Trial and Appeal Board of the USPTO) alleging invalidity of any of the PATENT RIGHTS within LICENSED FIELD in the TERRITORY at its sole discretion, subject to: 

(a) consulting with HPPI through a joint litigation committing comprising two appointees of each of Mayne Pharma and HPPI, which committee will
discuss the management and course of action with respect to such enforcement or defense, including without limitation, the selection of outside counsel, legal strategy, staff, the engagement of any third party consultants, experts or vendors, the
advancement of any legal theory or basis for infringement or defense, scope of discovery, deadlines or extensions for discovery, filing of motions, taking of depositions, providing admission or stipulations, schedule for hearings, proceedings before
the court, filing of appeals, commencement and conduct of settlement negotiations or any other actions affecting a Party’s rights or obligations or entailing the incurring of cost or expense; and 

(b) Mayne Pharma obtaining the express consent of HPPI prior to selecting counsel, bringing any suit in HPPI’s name, or entering into any
settlement, consent judgment or other voluntary final disposition of the suit, such consent not be unreasonably withheld, except that if JHU consents to HPPI enforcing any patent within the PATENT RIGHTS or defending any declaratory judgment action
or similar proceeding alleging invalidity of any of the PATENT RIGHTS then HPPI shall manage the conduct of any such enforcement or defense but will consult with Mayne Pharma on the same terms as would have applied under Paragraph 4.5A(a) and obtain
the prior written consent of Mayne Pharma prior to the events referred to in Paragraph 4.5A(b), such consent not be unreasonably withheld. 

4.6 Conduct of litigation where HPPI is a party. Where it is necessary or desirable for HPPI to be named as a party in any
litigation referred to in Paragraph 4.3 or 4.4, HPPI will do all acts and execute such legal papers as are reasonably requested by Mayne Pharma in connection with such litigation. The counsel selected by Mayne Pharma for the litigation (subject to
the express consent of HPPI, not to be unreasonably withheld) shall represent both 

  
 Page 9 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 
HPPI and Mayne Pharma. Notwithstanding the foregoing, if due to legal conflict, the parties cannot be represented by the same counsel, then each of JHU and Mayne Pharma shall have the right to
retain its own separate legal counsel, in which case, the fees of such separate legal counsel shall still be paid by HPPI. 
 4.7
Listing on the FDA Orange Book. At the applicable time, HPPI must use reasonable commercial efforts to list all patents comprised in the PATENT RIGHTS promptly in the FDA Orange Book for the LICENSED PRODUCT in the LICENSED FIELD. 

ARTICLE 5 
 OBLIGATIONS
OF THE PARTIES 
 5.1 Reports. HPPI shall provide to Mayne Pharma the following written reports according to the following
schedules. 
 (a) HPPI shall provide quarterly Royalty Reports, substantially in the format of Exhibit B and due within ***
the FIRST COMMERCIAL SALE occurs. Royalty Reports shall disclose the amount of LICENSED PRODUCT(S) and LICENSED SERVICE(S) sold, the total NET SALES and NET SERVICE REVENUES of such LICENSED PRODUCT(S) and LICENSED SERVICE(S), and the running
royalties due to Mayne Pharma as a result of NET SALES and NET SERVICE REVENUES by HPPI or any SUBLICENSEE thereof. Payment of any such royalties due shall accompany such Royalty Reports. 

(b) Until HPPI or any SUBLICENSEE has achieved a first commercial sale of a LICENSED PRODUCT or LICENSED SERVICE in the TERRITORY, or
received FDA market approval, HPPI shall provide to Mayne Pharma semiannual Diligence Reports, due within *** following the EFFECTIVE DATE of this Agreement. These Diligence Reports shall describe the technical efforts of HPPI or SUBLICENSEE
towards meeting its obligations under the terms of this Agreement. 
 (c) HPPI shall provide to Mayne Pharma Annual Reports within
*** following the EFFECTIVE DATE of this Agreement. Annual Reports shall include: 
  

	 	(i)	 evidence of insurance as required under Paragraph 10.4, or, a statement of why such insurance is not currently
required, and 

  

	 	(ii)	 notice of all FDA approvals of any LICENSED PRODUCT(S) or LICENSED SERVICE(S) obtained by HPPI or any
SUBLICENSEE, the patent(s) or patent application(s) licensed under this Agreement upon which such product or service is based, and the commercial name of such product or service, or, in the alternative, a statement that no FDA approvals have been
obtained. 

  
 Page 10 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 5.2 Records. HPPI shall make and retain, for a period of *** following
the period of each report required by Paragraph 5.1, true and accurate records, files and books of account containing all the data reasonably required for the full computation and verification of sales and other information required in Paragraph
5.1. Such books and records shall be in accordance with generally accepted accounting principles consistently applied. HPPI shall permit the inspection and copying of such records, files and books of account by Mayne Pharma, Accelas or their agents
during regular business hours upon *** written notice to HPPI. Such inspection shall not be made more than once each calendar year. All costs of such inspection and copying shall be paid by ***, provided that if any such inspection by
Mayne Pharma shall reveal that an error has been made in the amount equal to *** of such payment, such costs shall be borne by ***. 

5.3 Best Efforts. HPPI is responsible for the commercialization of the LICENSED PRODUCT(S) and LICENSED SERVICE(S) in the
LICENSED FIELD in the TERRITORY, including the conduct of all development programs, the submission and approval of the marketing authorizations, and payment of all associated fees and expenses, provided that JHU and Mayne Pharma must provide any
assistance reasonably requested by HPPI in seeking marketing authorizations (at HPPI’s expense). HPPI shall exercise best efforts to develop and to introduce the LICENSED PRODUCT(S) in the LICENSED FIELD into the commercial market as soon as
practicable, consistent with sound and reasonable business practice and judgement; thereafter, until the expiration or termination of this Agreement, HPPI shall endeavor to keep LICENSED PRODUCT(S) in the LICENSED FIELD reasonably available to the
public. HPPI shall also exercise reasonable efforts to develop LICENSED PRODUCT(S) suitable for different indications within the LICENSED FIELD, so that the PATENT RIGHTS can be commercialized as broadly and as speedily as good scientific and
business judgement would deem possible. 
 5.4 Patent Acknowledgement. HPPI agrees that all packaging containing individual
LICENSED PRODUCT(S) sold by HPPI or any SUBLICENSEE will be marked with the number of the applicable patent(s) licensed hereunder in accordance with patent laws in the TERRITORY. 

ARTICLE 6 

REPRESENTATIONS 

6.1 Duties of the Parties. JHU is not a commercial organization. It is an institute of research and education. Therefore,
JHU has no ability to evaluate the commercial potential of any PATENT RIGHTS or LICENSED PRODUCT or other license or rights granted in this Agreement. It is therefore incumbent upon HPPI to evaluate the rights and products in question, to examine
the materials and information provided by JHU, and to determine for itself the validity of any PATENT RIGHTS, its freedom to operate, and the value of any LICENSED PRODUCTS or SERVICES or other rights granted. 

6.2 PATENT RIGHTS PROVIDED “AS IS”; Representations by JHU. JHU has warranted via the Head License that it has good
and marketable title to the inventions claimed under PATENT RIGHTS with the exception of certain retained rights of the United States Government, which may apply if any part of the JHU research was funded in whole or in part by the United States
Government. JHU does not warrant the validity of any patents or that practice under such patents shall be free of infringement. EXCEPT AS EXPRESSLY SET FORTH IN THIS PARAGRAPH 6.2, EACH OF HPPI AND ANY SUBLICENSEE AGREE THAT THE PATENT RIGHTS ARE
PROVIDED “AS IS”, AND THAT EACH OF JHU, ACCELAS AND 

  
 Page 11 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 
MAYNE PHARMA MAKE NO REPRESENTATION OR WARRANTY WITH RESPECT TO THE PERFORMANCE OF LICENSED PRODUCT(S) AND LICENSED SERVICE(S) INCLUDING THEIR SAFETY, EFFECTIVENESS, OR COMMERCIAL VIABILITY. EACH
OF JHU, ACCELAS AND MAYNE PHARMA DISCLAIM ALL WARRANTIES WITH REGARD TO PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT, INCLUDING, BUT NOT LIMITED TO, ALL WARRANTIES, EXPRESSED OR IMPLIED, OF MERCHANTABILITY AND FITNESS FOR ANY PARTICULAR
PURPOSE. NOTWITHSTANDING ANY OTHER PROVISION OF THIS AGREEMENT, JHU ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF JHU AND INVENTORS, AND EACH OF ACCELAS AND MAYNE PHARMA ADDITIONALLY DISCLAIM ALL OBLIGATIONS AND LIABILTIES ON
THE PART OF ACCELAS AND MAYNE PHARMA FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL, AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF ANY OF JHU, ACCELAS OR MAYNE PHARMA HAS BEEN
ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING OUT OF OR IN CONNECTION WITH THE MANUFACTURE, USE, OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. HPPI AND ANY SUBLICENSEE ASSUME ALL RESPONSIBILITY AND
LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT AND/OR SERVICE MANUFACTURED, USED, OR SOLD BY HPPI OR ANY SUBLICENSEE WHICH IS A LICENSED PRODUCT(S) OR LICENSED SERVICE(S) AS DEFINED IN THIS AGREEMENT. 

6.3 Representations and Covenants of Mayne Pharma. 

(a) Mayne Pharma warrants to HPPI that (i) it is entitled to grant HPPI the sublicence of the PATENT RIGHTS on the terms and conditions
set out in this Agreement; and (ii) Exhibit C (with commercial in confidence information redacted) is a true and complete copy of the Accelas Sublicense; and (iii) it has not, and will not during the term of this Agreement, impose
in favor of any third party any mortgage, pledge, lien, encumbrance, charge or other security interest over the Sublicense or any PATENT RIGHTS, whether that mortgage, pledge, lien, encumbrance, charge or other security interest has a material,
adverse impact on HPPI’s rights under this Agreement. 
 (b) Mayne Pharma covenants to HPPI that it will use reasonable commercial
efforts to comply with its obligations under the Accelas Sublicense and will not terminate the Accelas Sublicense without cause except with the prior written consent of HPPI, such consent not to be unreasonably withheld or delayed. 

ARTICLE 7 

INDEMNIFICATION 

7.1 Indemnification. HPPI shall be responsible for injuries or losses to third parties arising from or related to HPPI’s
own acts or omissions, or caused by arising from HPPI’s use or third party use of LICENSED PRODUCT(S) sold by HPPI or any SUBLICENSEE and LICENSED SERVICE(S) performed by HPPI or any SUBLICENSEE, or arising as a

  
 Page 12 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 
consequence of the exercise by HPPI or any SUBLICENSEE(S) of any rights granted in this Agreement. JHU and the Inventors will have no legal liability exposure to third parties if JHU does not
license the LICENSED PRODUCT(S) and LICENSED SERVICE(S), and any royalties JHU and the Inventors may receive under the Head License is not adequate compensation for such legal liability exposure. Therefore, JHU requires HPPI to protect JHU and
Inventors from such exposure to the same manner and extent to which insurance, if available, would protect JHU and Inventors. Furthermore, JHU and the Inventors will not, under the provisions of the Head License, this Agreement or otherwise, have
control over the manner in which HPPI or any SUBLICENSEE(S) or those operating for its account or third parties who purchase LICENSED PRODUCT(S) or LICENSED SERVICE(S) from any of the foregoing entities, develop, manufacture, market or practice the
inventions of LICENSED PRODUCT(S) and LICENSED SERVICE(S). Therefore, HPPI and any SUBLICENSEE shall indemnify, defend with counsel reasonably acceptable to JHU, and hold JHU, The Johns Hopkins Health Systems, their present and former trustees,
officers, Inventors of PATENT RIGHTS, agents, faculty, employees and students harmless as against any judgments, fees, expenses, or other costs arising from or incidental to any product liability or other lawsuit, claim, demand or other action
brought as a consequence of the practice of said inventions by any of the foregoing entities, whether or not JHU or said Inventors, either jointly or severally, is named as a party defendant in any such lawsuit and whether or not JHU or the
Inventors are alleged to be negligent or otherwise responsible for any injuries to persons or property. Practice of the inventions covered by LICENSED PRODUCT(S) and LICENSED SERVICE(S), by an agent or any SUBLICENSEE(S) or a third party on behalf
of or for the account of HPPI or by a third party who purchases LICENSED PRODUCT(S) and LICENSED SERVICE(S) from HPPI, shall be considered HPPI’s practice of said inventions for purposes of this Paragraph. The obligation of HPPI to defend and
indemnify as set out in this Paragraph shall survive the termination of this Agreement, shall continue even after assignment of rights and responsibilities to an AFFILIATED COMPANY (but not any other assignment by HPPI in accordance with Paragraph
10.8), and shall not be limited by any other limitation of liability elsewhere in this Agreement. 
 7.2 Indemnification
Procedure. A party intending to claim indemnification under this Agreement (“Indemnitee”) shall promptly notify the indemnifying party (“Indemnitor”) in writing of any lawsuit, claim, demand or other action, or
any judgments, fees, expenses or other costs in respect of which the Indemnitee intends to claim such indemnification. The Indemnitee reasonably shall cooperate with the Indemnitor in the defense of the lawsuit, claim, demand or other action, and
the Indemnitor shall have the right to control the defense and/or settlement of the lawsuit, claim, demand or other action; provided, however, that any such settlement shall not require the Indemnitee to admit any liability or pay any amounts
without the prior written consent of such Indemnitee. The Indemnitee shall use reasonable efforts to mitigate any fees, expenses or other costs. 

  
 Page 13 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 ARTICLE 8 

CONFIDENTIALITY 

8.1 Confidentiality. If necessary, the parties will exchange information in respect of the subject matter of this Agreement,
which they consider to be confidential. The recipient of such information agrees to keep it confidential provided such information is marked as confidential at the time it is sent to the recipient, or if it is disclosed orally, summarised in writing
and identified as ‘confidential’ within *** after its presentation (provided that a failure to do so shall not detract from the obligations in this Paragraph where it was reasonably apparent that such information was confidential in
nature). Without limitation, the recipient agrees to employ all reasonable efforts to maintain the information secret and confidential, such efforts to be no less than the degree of care employed by the recipient to preserve and safeguard its own
confidential information. The information shall not be disclosed or revealed to anyone except employees of the recipient who have a need to know the information and who have entered into a secrecy agreement with the recipient under which such
employees are required to maintain confidential the proprietary information of the recipient and such employees shall be advised by the recipient of the confidential nature of the information and that the information shall be treated accordingly.

 The obligations of this Paragraph 8.1 shall also apply to any SUBLICENSEE(S) provided such information by HPPI. Mayne Pharma’s,
HPPI’s, and SUBLICENSEES’ obligations under this Paragraph 8.1 shall extend until *** after the termination of this Agreement. 

The obligations of this Paragraph 8.1 shall apply to confidential information exchanged prior to, on or after the EFFECTIVE DATE in connection
with this Agreement or the transactions contemplated under it. To avoid doubt, the parties agree that nothing in this Agreement detracts from the restrictions on use and disclosure of confidential information under the Second Amended and Restated
Supply and License Agreement, dated May 15, 2015, by and between Mayne Pharma Ventures Pty Ltd., an Affiliated Company of Mayne Pharma, and HPPI. 

8.2 Exceptions. The recipient’s obligations under Paragraph 8.1 shall not extend to any part of the information: 

(a) that can be demonstrated to have been in the public domain or publicly known and readily available to the trade or the public prior to the
date of the disclosure; or 
 (b) that can be demonstrated, from written records to have been in the recipient’s possession or readily
available to the recipient from another source not under obligation of secrecy to the disclosing party prior to the disclosure; or 
 (c)
that becomes part of the public domain or publicly known by publication or otherwise, not due to any unauthorized act by the recipient; or 

(d) that is demonstrated from written records to have been developed by or for the receiving party without reference to confidential
information disclosed by the disclosing party. 
 (e) that is required to be disclosed by law, government rule or regulation or court or
arbitration order, or any applicable stock exchange. 

  
 Page 14 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 8.3 Right to Publish. JHU may publish manuscripts, abstracts or the like
describing the PATENT RIGHTS and inventions contained therein provided confidential information of HPPI as contemplated in Paragraph 8.1, is not included or without first obtaining approval from HPPI to include such confidential information.
Otherwise, JHU and the Inventors shall be free to publish manuscripts and abstracts or the like directed to the work done at JHU related to the licensed technology without prior approval. 

ARTICLE 9 

TERM & TERMINATION 

9.1 Term. The term of this Agreement shall commence on the EFFECTIVE DATE and shall continue until the earlier of:
(a) the date of expiration of the last to expire patent included within PATENT RIGHTS in the TERRITORY; or (b) notice by Mayne Pharma with immediate effect promptly after termination or expiry of the Head License or Accelas Sublicense in
circumstances where Mayne Pharma no longer has the right to obtain an EXCLUSIVE LICENSE to make, have made, use, import, offer for sale and sell the LICENSED PRODUCT(S) and to provide the LICENSED SERVICE(S) in the TERRITORY under the PATENT RIGHTS
in the LICENSED FIELD. 
 9.2 Termination By Either Party. This Agreement may be terminated by either party giving
written notice to the other party, with effect immediately (or any later date specified in the notice), in the event that the other party (a) files or has filed against it a petition under the Bankruptcy Act, makes an assignment for the benefit
of creditors, has a receiver appointed for it or a substantial part of its assets, otherwise takes advantage of or has any action taken in respect of it under any statute or law designed for relief of debtors, or (having regard to its legal
structure and the jurisdiction in which it is incorporated or operates) any event analogous to one of the foregoing events happens to it or (b) fails to perform or otherwise breaches any of its obligations hereunder, if either
(i) following the giving of notice by the terminating party of its intent to terminate and stating the grounds therefor, the party receiving such notice shall not have cured the failure or breach within *** or (ii) that failure to
perform or breach is not capable of being cured. In no event, however, shall such notice or intention to terminate be deemed to waive any rights to damages or any other remedy which the party giving notice of breach may have as a consequence of such
failure or breach. 
 9.3 Termination by Mayne Pharma. Mayne Pharma may terminate this Agreement with immediate effect by
notice to HPPI if the THIRD SLA expires or is terminated. 
 9.4 Obligations and Duties upon Termination. If this Agreement is
terminated, both parties shall be released from all obligations and duties imposed or assumed hereunder to the extent so terminated, except as expressly provided to the contrary in this Agreement. Upon termination, both parties shall cease any
further use of the confidential information disclosed to the receiving party by the other party. Termination of this Agreement, for whatever reason, shall not affect the obligation of either party to make any payments for which it is liable prior to
or upon such termination. Termination shall not affect Mayne Pharma’s right to recover unpaid royalties, fees, reimbursement for patent expenses, or other forms of financial compensation incurred prior to termination. Upon termination HPPI
shall submit a final royalty report to Mayne Pharma and any royalty payments, fees, unreimbursed patent expenses and other financial compensation due Mayne Pharma shall become immediately payable. Furthermore, upon termination of this Agreement, as
between Mayne Pharma and HPPI, all rights in and to the licensed technology shall revert immediately to Mayne Pharma at no cost to Mayne Pharma. 

  
 Page 15 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 ARTICLE 10 

MISCELLANEOUS 
 10.1
Use of Name. HPPI and any SUBLICENSEE shall not use the name of The Johns Hopkins University or The Johns Hopkins Health System or any of its constituent parts, such as the Johns Hopkins Hospital or any contraction thereof or the name of
Inventors in any advertising, promotional, sales literature or fundraising documents without prior written consent from an authorized representative of JHU. HPPI and any SUBLICENSEE(S) shall allow at least *** notice of any proposed public
disclosure for JHU’s review and comment or to provide written consent. 
 10.2 No Partnership. Nothing in this Agreement
shall be construed to create any agency, employment, partnership, joint venture or similar relationship between the parties other than that of a licensor/licensee. Neither party shall have any right or authority whatsoever to incur any liability or
obligation (express or implied) or otherwise act in any manner in the name or on the behalf of the other, or to make any promise, warranty or representation binding on the other. 

10.3 Notice of Claim. Each party shall give the other or its representative immediate notice of any suit or action filed, or
prompt notice of any claim made, against them arising out of the performance of this Agreement or arising out of the practice of the inventions licensed hereunder. 

10.4 Product Liability. Prior to initial human testing or first commercial sale of any LICENSED PRODUCT(S) or LICENSED
SERVICE(S) in the LICENSED FIELD in the TERRITORY, HPPI shall establish and maintain product liability or other appropriate insurance coverage in the minimum amount of *** per claim and will annually present evidence to JHU or Mayne Pharma
that such coverage is being maintained. Upon JHU’s or Mayne Pharma’s request, HPPI will furnish it with a Certificate of Insurance of each product liability insurance policy obtained. JHU shall be listed as an additional insured in
HPPI’s said insurance policies. If such Product Liability insurance is underwritten on a ‘claims made’ basis, HPPI agrees that any change in underwriters during the term of this Agreement will require the purchase of ‘prior
acts’ coverage to ensure that coverage will be continuous throughout the term of this Agreement. 
 10.5 Governing Law.
For consistency with the Head License which is with JHU (a Maryland corporation) and are governed by the laws of the State of Maryland, and for consistency with the Accelas Sublicense which is governed by the laws of the State of Maryland, this
Agreement shall be construed, and legal relations between the parties hereto shall be determined, in accordance with the laws of the State of Maryland applicable to contracts solely executed and wholly to be performed within the State of Maryland
without giving effect to the principles of conflicts of laws. EACH PARTY WAIVES ALL RIGHTS TO ANY TRIAL BY JURY IN ALL LITIGATION RELATING TO OR ARISING OUT OF THIS AGREEMENT. 

  
 Page 16 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 10.5A Resolution of Disputes. A party must not start court proceedings (except
proceedings seeking interlocutory relief for the protection of intellectual property or confidential information, or proceedings in relation to debt recovery) for a dispute arising out of this Agreement, including the breach, termination or
invalidity of this Agreement, (“Dispute”) unless it has complied with this Paragraph 10.5A. A party claiming that a Dispute has arisen must notify the other party giving details of the Dispute. When such a notice is given, each
party’s respective representatives must first attempt to resolve the Dispute and, if they cannot resolve the Dispute within *** after the notice is given, they must refer the Dispute to each party’s chief executive officer who must
then attempt to resolve it. If the parties cannot resolve the Dispute within six weeks after the notice of the Dispute is given (or longer period if the parties to the Dispute agree in writing), either party may refer the Dispute to arbitration. If
either party exercises that right, the Dispute must be settled by arbitration in accordance with the expedited procedure set out in the Singapore International Arbitration Centre Rules for Arbitration, as at present in force and as may be amended by
the rest of this Paragraph 10.5A. The place of arbitration will be Singapore. There will only be one arbitrator. The arbitration must be conducted in English. The decision of the arbitrator shall be final and binding and any award rendered
thereon may be entered in any court having jurisdiction. The parties hereby waive any and all objections and defenses to such jurisdiction regardless of the nature of such objection or defense. 

10.6 Notice. All notices or communication required or permitted to be given by either party hereunder shall be deemed
sufficiently given if mailed by registered mail or certified mail, return receipt requested, to the other party at its respective address set forth below or to such other address as one party shall give notice of to the other from time to time
hereunder. 
  

			
	If to Mayne Pharma:	  	 General Counsel
 Mayne Pharma International Pty
Ltd
 1538 Main North Road, Salisbury South, SA 5106
 Melbourne
Vic 3000
 Australia
 Facsimile: +61 3 9614 7022

		
	If to HPPI:	  	 President and CEO
 HedgePath Pharmaceuticals,
Inc.
 324 South Hyde Park Avenue Suite 350
 Tampa, FL 33606,
United States
 Facsimile: +1 813-527-0500

 A notice given in accordance with Paragraph 10.6 takes effect when taken to be received (or at a later time specified in it),
and is taken to be received: (i) if hand delivered or sent by reputable international courier, on delivery; (ii) if sent by prepaid post, on the second business day after the date of posting (or on the seventh business day after the date
of posting if posted to or from a place outside Australia); or (iii) if sent by facsimile, when the sender’s facsimile system generates a message confirming successful transmission of the entire notice unless, within 8 business hours after
the transmission, the recipient informs the sender that it has not received the entire notice, but if the delivery, receipt or transmission is not on a business day or is after 5.00pm on a business day, the notice is taken to be received at 9.00am
on the next business day. 

  
 Page 17 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 10.7 Compliance with All Laws. In all activities undertaken pursuant to this
Agreement, both Mayne Pharma and HPPI covenant and agree that each will in all material respects comply with such Federal, state and local laws and statutes, as may be in effect at the time of performance and all valid rules, regulations and orders
thereof regulating such activities. 
 10.8 Successors and Assigns. Neither this Agreement nor any of the rights or
obligations created herein, except for the right to receive any remuneration hereunder, may be assigned or novated by either party, in whole or in part, without the prior written consent of the other party (which consent must not be unreasonably
withheld or delayed), except that either party shall be free to assign or novate this Agreement in connection with any sale of substantially all of its assets without the consent of the other and Mayne Pharma shall be free to assign or novate this
Agreement to an AFFILIATED COMPANY who is an assignee of Mayne Pharma’s rights and obligations under the Accelas Sublicense. This Agreement shall bind and inure to the benefit of the successors and permitted assigns of the parties hereto. 

10.9 No Waivers; Severability. No waiver of any breach of this Agreement shall constitute a waiver of any other breach of the
same or other provision of this Agreement, and no waiver shall be effective unless made in writing. Any provision hereof prohibited by or unenforceable under any applicable law of any jurisdiction shall as to such jurisdiction be deemed ineffective
and deleted herefrom without affecting any other provision of this Agreement. It is the desire of the parties hereto that this Agreement be enforced to the maximum extent permitted by law, and should any provision contained herein be held by any
governmental agency or court of competent jurisdiction to be void, illegal and unenforceable, the parties shall negotiate in good faith for a substitute term or provision which carries out the original intent of the parties. 

10.10 Entire Agreement; Amendment. HPPI and Mayne Pharma acknowledge that they have read this entire Agreement and that this
Agreement, including the attached Exhibits constitutes the entire understanding and contract between the parties hereto and supersedes any and all prior or contemporaneous oral or written agreements or communications with respect to the subject
matter hereof, all of which agreements and communications are merged herein. It is expressly understood and agreed that (i) there being no expectations to the contrary between the parties hereto, no usage of trade, verbal agreement or another
regular practice or method dealing within any industry or between the parties hereto shall be used to modify, interpret, supplement or alter in any manner the express terms of this Agreement; and (ii) this Agreement shall not be modified,
amended or in any way altered except by an instrument in writing signed by both of the parties hereto. 
 10.11 Delays or
Omissions. Except as expressly provided herein, no delay or omission to exercise any right, power or remedy accruing to any party hereto, shall impair any such right, power or remedy to such party nor shall it be construed to be a waiver of any
such breach or default, or an acquiescence therein, or in any similar breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or

  
 Page 18 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 
approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on the part of any party of any provisions or conditions of this Agreement,
must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies either under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 

10.12 Force Majeure. If either party fails to fulfill its obligations hereunder (other than an obligation for the payment of
money), when such failure is due to an act of God, or other circumstances beyond its reasonable control, including but not limited to fire, flood, civil commotion, riot, war (declared and undeclared), revolution, or embargoes, then said failure
shall be excused for the duration of such event and for such a time thereafter as is reasonable to enable the parties to resume performance under this Agreement, provided however, that in no event shall such time extend for a period of more than
***. If a failure to perform continues for more than ***, the other party may terminate this Agreement immediately by giving notice to the affected party. 

10.13 Further Assurances. Each party shall, at any time, and from time to time, prior to or after the EFFECTIVE DATE of this
Agreement, at reasonable request of the other party, execute and deliver to the other such instruments and documents and shall take such actions as may be required to more effectively carry out the terms of this Agreement. 

10.14 Survival. All representations, warranties, covenants and agreements made herein and which by their express terms or by
implication are to be performed after the execution and/or termination hereof, or are prospective in nature, shall survive such execution and/or termination, as the case may be. This shall include Paragraph 3.7 (Payment), 3.10 (Withholding tax) 5.2
(Records), and Articles 6, 7, 8, 9.4 and 10, and Paragraphs 4.3 to 4.6 where Mayne Pharma elects to continue with such litigation after execution and/or termination. 

10.15 No Third Party Beneficiaries. Nothing in this Agreement shall be construed as giving any person, firm, corporation or
other entity, other than the parties hereto and their successors and permitted assigns, any right, remedy or claim under or in respect of this Agreement or any provision hereof, except as expressly set out in this Agreement. 

10.16 Headings. Article headings are for convenient reference and not a part of this Agreement. All Exhibits are incorporated
herein by this reference. 
 10.17 Counterparts. This Agreement may be executed in counterparts (including electronic
counterparts), each of which shall be deemed an original and all of which when taken together shall be deemed but one instrument. Delivery of an executed signature page of this agreement by facsimile transmission or electronic transmission shall be
as effective as delivery of a manually executed counterpart hereof. 
 10.18 Costs. Each party must bear its own costs of
preparing and executing this Agreement. 

  
 Page 19 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 [Signature page follows] 

  
 Page 20 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 IN WITNESS WHEREOF, Mayne Pharma and HPPI have duly executed this Amended and Restated
Sublicense Agreement as of the date first written above. 
  

	
	MAYNE PHARMA INTERNATIONAL PTY LTD
	
	/s/ Nick Freeman
	Scott Richards
	Director
	
	December 17, 2018
	(Date)

  

	
	HEDGEPATH PHARMACEUTICALS, INC.
	
	/s/ Nicholas J. Virca
	Nicholas J. Virca
	 President and CEO

	
	December 17, 2018
	(Date)

  
 Page 21 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 EXHIBIT A 

License fee: ***. 
 Minimum annual royalty:
*** per year, commencing in accordance with Paragraph 3.2. 
 Royalty: *** of NET SALES of an itraconazole LICENSED PRODUCT in the
LICENSED FIELD and NET SERVICE REVENUES in the LICENSED FIELD in the TERRITORY where a patent comprised in the PATENT RIGHTS is and remains registered at the time the relevant sales revenues and fees are billed. 

Where an itraconazole LICENSED PRODUCT has exclusivity in the LICENSED FIELD in the TERRITORY due solely to the PATENT RIGHTS, a further royalty supplement of
*** of NET SALES and NET SERVICE REVENUES in the TERRITORY except that where Accelas, itself or through any third party, imports, promotes, distributes or sells any product substantially the same as, or similar to, or substitutable for, the
LICENSED PRODUCT or providers services substantially the same as, or similar to, the LICENSED SERVICES, in each case in the LICENSED FIELD in the TERRITORY, in which case no royalty supplement applies. . 

Milestone Payments: HPPI shall pay to Mayne Pharma the milestone payments set forth below, in each case payable only provided that any claim in
the HEDGEHOG PATENT in the TERRITORY directed to administering orally itraconazole remains valid at the time payment falls due:  
 *** 

  
 Page 22 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 EXHIBIT B 

Royalty Report 
 *** 

  
 Page 23 

 Confidential Treatment Requested by HedgePath Pharmaceuticals, Inc., 

IRS Employer Identification No. 30-0793665 
  

 EXHIBIT C 

Accelas Sublicense 

  
 Page 24EX-10.7

 Exhibit 10.7 

AGREEMENT 
 This
AGREEMENT (this “Agreement”) is entered into by and among HEDGEPATH PHARMACEUTICALS, INC., a Delaware corporation (“HPPI”), MAYNE PHARMA VENTURES PTY LTD, an Australian company ACN 168 896 357
(“Mayne Pharma”), and MAYNE PHARMA INTERNATIONAL PTY LTD, an Australian company ACN 007 870 984 (“Mayne Pharma International” and together with Mayne Pharma, collectively, the “Mayne Pharma
Companies” and each, a “Mayne Pharma Company”), effective December 17, 2018 (the “Effective Date”). Any capitalized term used herein but not otherwise defined shall have the meaning ascribed to such
term in the Existing Supply and License Agreement (as hereinafter defined). 
 RECITALS 

WHEREAS, HPPI and Mayne Pharma are parties to that certain Second Amended and Restated Supply and License Agreement, dated as of
May 15, 2015, as amended by that certain Amendment No. 1 to Second Amended and Restated Supply and License Agreement, effective as of November 22, 2016 and that certain Amendment No. 2 to Second Amended and Restated Supply and
License Agreement and Amendment No. 1 to Sublicense Agreement, effective as of January 10, 2018 (the “Existing Supply and License Agreement”); 

WHEREAS, HPPI and Mayne Pharma International are parties to that certain Sublicense Agreement, dated August 31, 2015, as amended
by that certain Amendment No. 2 to Second Amended and Restated Supply and License Agreement and Amendment No. 1 to Sublicense Agreement, effective as of January 10, 2018 (the “Existing Angiogenesis and Hedgehog Patent
Sublicense Agreement”); 
 WHEREAS, pursuant to that certain Securities Purchase Agreement, dated as of January 8,
2018, by and between HPPI and Mayne Pharma, HPPI (i) filed with the Secretary of State of Delaware a Certificate of Designation of Series B Convertible Preferred Stock of HedgePath Pharmaceuticals, Inc., as corrected by a Certificate of
Correction of Certificate of Designation of Series B Convertible Preferred Stock of HedgePath Pharmaceuticals, Inc. (the “Series B Certificate of Designation”), and (ii) issued to Mayne Pharma 5,797,102 shares (the
“Series B Preferred Shares”) of Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”), of HPPI; 

WHEREAS, pursuant to Section 5.3 of the Existing Supply and License Agreement and Section 10.19 of the Existing Angiogenesis
and Hedgehog Patent Sublicense Agreement, within sixty days from the date Mayne Pharma receives written notice of a Target Failure or, failing timely provision of such notice, on Mayne Pharma becoming aware of such Target Failure, Mayne Pharma,
among other things, may, by notice to HPPI elect to assume the right to, on its own and at its sole cost and expenses, exploit any Product solely in the BCCNS Field in the Territory and Mayne Pharma International may, by notice to HPPI elect to
exclude the BCCNS Field from the Licensed Field (as defined in the Existing Angiogenesis and Hedgehog Patent Sublicense Agreement) (collectively, the “Mayne BCCNS Assumption Right”); 

WHEREAS, each of the Existing Supply and License Agreement and the Existing Angiogenesis and Hedgehog Patent Sublicense Agreement
provides that a “Target Failure” means the earlier to occur of (i) December 31, 2018, if the FDA has not accepted the filing of the NDA by 

 
such date; provided that such date shall be automatically extended in the event that the NDA is filed with the FDA during December 2018 to a date which is 30 days from the date of such filing and
(ii) the Target Launch Date, if the commercial launch of Licensed Product in the Territory in the BCCNS Field has not been achieved by HPPI by such date; 

WHEREAS, on October 9, 2018, HPPI publicly announced that it anticipated filing its NDA for SUBA BCCNS with the FDA in the first
quarter of 2019; 
 WHEREAS, while exploring alternatives to file the NDA for SUBA BCCNS so as to avoid a “Target Failure”,
the Board of Directors of HPPI formed a committee comprised of disinterested directors who are independent of Mayne Pharma (the “Independent Committee”) to evaluate, negotiate and approve or disapprove of any potential transaction
with Mayne Pharma with respect to the Mayne BCCNS Assumption Right and related matters; 
 WHEREAS, after exploring all alternatives
in the exercise of their business judgment, the Independent Committee has (i) negotiated the terms and conditions of this Agreement and the agreements and transactions contemplated hereby on behalf of HPPI, (ii) determined that it is
advisable and in the best interests of HPPI and its stockholders other than Mayne Pharma to enter into this Agreement and consummate the transactions contemplated hereby and (iii) approved the execution, delivery and performance of this
Agreement and the consummation of the transactions contemplated hereby; 
 WHEREAS, in furtherance of the foregoing, HPPI and Mayne
Pharma desire to amend and restate the Existing Supply and License Agreement to effect certain amendments thereto, upon the terms and subject to the conditions set forth in a Third Amended and Restated Supply and License Agreement, in the form
attached hereto as Exhibit A (the “Third Amended and Restated Supply and License Agreement”); 
 WHEREAS, in
furtherance of the foregoing, HPPI and Mayne Pharma International desire to amend and restate the Existing Angiogenesis and Hedgehog Patent Sublicense Agreement to effect certain amendments thereto, upon the terms and subject to the conditions set
forth in an Amended and Restated Sublicense Agreement, in the form attached hereto as Exhibit B (the “Amended and Restated Sublicense Agreement”); 

WHEREAS, in furtherance of the foregoing, HPPI and Mayne Pharma desire to amend and restate the Series B Certificate of Designation to
effect certain amendments thereto; and 
 WHEREAS, as part of the integrated transactions contemplated by the foregoing, HPPI desires
for Mayne Pharma to agree, and Mayne Pharma has agreed, to undertake certain actions with respect to HPPI in the manner as set forth herein. 

NOW, THEREFORE, in consideration of the promises and agreements of the parties hereto and for other good and valuable consideration,
the receipt and sufficiency of which is hereby acknowledged, and intending to be legally bound, the parties hereto hereby agree as follows: 

1.    Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms used in this
Agreement shall be construed to have the meanings set forth or referenced below: 

  
 2 

 1.1    “DGCL” means the Delaware General Corporation
Law. 
 1.2    “Equity Holders Agreement” means that certain Amended and Restated Equity Holders
Agreement, dated as of May 15, 2015, as amended by Amendment No. 1 to the Amended and Restated Equity Holders Agreement dated December 17, 2015, by and among Mayne Pharma, HPPI and the other parties thereto. 

1.3    “Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended. 

1.4    “SEC” means the U.S. Securities and Exchange Commission. 

1.5    “Transaction Documents” means this Agreement, the Third Amended and Restated Supply and License
Agreement, the Amended and Restated Sublicense Agreement and the Restated Series B Certificate of Designation (as defined in Section 4.5 hereof). 

2.    Third Amended and Restated Supply and License Agreement. Concurrently with the execution and delivery of this
Agreement, (a) Mayne Pharma shall deliver to HPPI a duly executed counterpart to the Third Amended and Restated Supply and License Agreement and (b) HPPI shall deliver to Mayne Pharma a duly executed counterpart to the Third Amended and
Restated Supply and License Agreement. The effectiveness of the Third Amended and Restated Supply and License Agreement shall not be conditioned on the effectiveness of any other transaction or action contemplated by this Agreement. 

3.    Amended and Restated Sublicense Agreement. Concurrently with the execution and delivery of this Agreement,
(a) Mayne Pharma International shall deliver to HPPI a duly executed counterpart to the Amended and Restated Sublicense Agreement and (b) HPPI shall deliver to Mayne Pharma International a duly executed counterpart to the Amended and
Restated Sublicense Agreement. The effectiveness of the Amended and Restated Sublicense Agreement shall not be conditioned on the effectiveness of any other transaction or action contemplated by this Agreement. 

4.    Restated Series B Certificate of Designation, Election of HPPI Board and Increase in EIP. 

4.1    Immediately following the execution and delivery of this Agreement, Mayne Pharma (in its capacity as the holder of
more than 50% of the outstanding voting securities of HPPI) shall execute and deliver to HPPI a stockholder consent in lieu of a special meeting of the stockholders of HPPI (the “Stockholder Consent”) to vote or cause to be voted
all of the shares of common stock, par value $0.0001 per share, of HPPI (the “Common Stock”), and all Series B Preferred Shares held by Mayne Pharma in favor of: (a) the adoption of the Restated Series B Certificate of
Designation, (b) the election of each Current Director (as defined in Section 5.2 hereof) to serve on the Board of Directors of HPPI for a one-year term that expires at the next annual
meeting of HPPI’s stockholders or until his earlier death, resignation or removal and (c) the approval of an increase in the size of HPPI’s 2014 Equity Incentive Plan (the “EIP”) by 11,000,000 shares of Common Stock
from 32,583,475 shares to 43,583,475 shares; provided, however, that neither this Section 4.1 nor Mayne Pharma’s execution and delivery of the Stockholder Consent contemplated hereby shall in any way limit, or be construed as
any waiver of, any of Mayne Pharma’s rights under the Equity Holders Agreement. 

  
 3 

 4.2    As soon as practicable following HPPI’s receipt of the
Stockholder Consent contemplated by Section 4.1 of this Agreement, HPPI shall prepare and file with the SEC a written information statement of the type contemplated by Rule 14c-2 of the Exchange Act
containing the information specified in Schedule 14C under the Exchange Act concerning the actions taken pursuant to the Stockholder Consent (as amended and supplemented, the “Information Statement”) and thereafter shall promptly
mail to HPPI’s stockholders notice of such action by written consent as required by Section 228(e) of the DGCL. HPPI and Mayne Pharma will cooperate and consult with each other in the preparation of the Information Statement. HPPI agrees
that it will not file the Information Statement, or any amendment or supplement thereto, with the SEC without providing Mayne Pharma and its counsel a reasonable opportunity to review and comment thereon (which comments shall be reasonably
considered by HPPI). 
 4.3    HPPI agrees to use its commercially reasonable efforts to ensure that the Information
Statement (a) except for information provided to HPPI by Mayne Pharma, will not on the date it is first mailed to the stockholders of HPPI contain any untrue statement of a material fact or omit to state any material fact required to be stated
therein in order to make the statements therein, in light of the circumstances under which they are made, not misleading and (b) will comply as to form in all material respects with the applicable requirements of the Exchange Act. If, at any
time prior to the date that is twenty (20) days after the Information Statement is first mailed to the stockholders of HPPI, any information relating to HPPI or Mayne Pharma or any of their respective Affiliates, officers or directors should be
discovered by HPPI or Mayne Pharma which is required to be set forth in an amendment or supplement to the Information Statement, so that the Information Statement shall not contain any untrue statement of a material fact or omit to state any
material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they are made, not misleading, the party hereto that discovers such information shall promptly notify the
other parties hereto, and an appropriate amendment or supplement describing such information shall be filed with the SEC and, to the extent required by applicable law, disseminated to the stockholders of HPPI. 

4.4    HPPI agrees to (a) notify Mayne Pharma and its counsel, as soon as reasonably practicable, of the receipt of
any comments from the SEC with respect to the Information Statement and any request by the SEC for any amendment to the Information Statement or for additional information and (b) provide Mayne Pharma and its counsel with copies of all written
correspondence between HPPI and the SEC with respect to the Information Statement. HPPI agrees to use its commercially reasonable efforts to resolve, and each of HPPI and Mayne Pharma agrees to consult and cooperate with the other in resolving, all
SEC comments with respect to the Information Statement as promptly as practicable after receipt thereof and to cause the Information Statement in definitive form to be cleared by the SEC and mailed to the stockholders of HPPI as promptly as
reasonably practicable following filing with the SEC. HPPI agrees to consult with Mayne Pharma prior to responding to SEC comments with respect to the preliminary Information Statement. 

4.5    As soon as twenty (20) calendar days have elapsed since HPPI mailed to its stockholders the Information
Statement in definitive form as contemplated by Rule 14c-2 promulgated under the Exchange Act, HPPI shall adopt and file with the Secretary of State of Delaware an Amended and Restated Certificate of
Designation of Series B Convertible Preferred Stock, in the form attached hereto as Exhibit C (the “Restated Series B Certificate of Designation”). 

  
 4 

 5.    Additional Agreements. 

5.1    From the period beginning on the Effective Date and ending three (3) years from the Effective Date, in the
event that HPPI asks its stockholders (whether at a meeting of stockholders or pursuant to a written consent of stockholders) to vote on or approve a proposal to effect a reverse split of HPPI’s capital stock for the purpose of uplisting the
Common Stock to a U.S. national securities exchange (a “Reverse Stock Split Proposal”), the Mayne Pharma Companies (on behalf of themselves and all entities identified as “Reporting Persons” in Mayne Pharma’s Schedule
13D/A filed with the U.S. Securities and Exchange Commission on November 5, 2018 (together with the Mayne Pharma Companies and the officers, directors, employees, affiliates, agents or representatives of such entities, the “Mayne Pharma
Group”) agrees to vote or cause to be voted (in person, by proxy or by action by written consent, as applicable) all shares of HPPI’s voting capital stock that either Mayne Pharma Company then owns or over which Mayne Pharma has voting
control in favor of the adoption and approval of any such Reverse Stock Split Proposal. It is agreed that the Reverse Stock Split Proposal may take the form of an authorization based on a range of ratios for the reverse stock split, with authority
being granted to the HPPI Board of Directors (or a designated committee thereof) to determine the final ratio of the reverse stock split, provided such range is reasonable in connection with the uplisting of the Common Stock to a U.S. national
securities exchange. 
 5.2    Effective upon and subject to the full execution and delivery by the applicable parties
of each of this Agreement, the Third Amended and Restated Supply and License Agreement and the Amended and Restated Sublicense Agreement, and in accordance with Section 4.9(b)(iv) of the Equity Holders Agreement, Mayne Pharma hereby consents
and agrees to an increase in the number of shares of Common Stock that HPPI may issue under the EIP to 17,624,000 shares from the current limit of 6,624,000 shares, with the agreement and understanding that such increase will be utilized by HPPI
during the period from the Effective Date through December 31, 2021. 
 5.3    Following the execution and delivery
of this Agreement, HPPI and Mayne Pharma shall jointly issue a mutually agreeable press release announcing this Agreement and the transactions contemplated hereby (the “Joint Press Release”). Neither HPPI nor any member of the Mayne
Pharma Group shall make any public statements inconsistent with the Joint Press Release, except as required by law or the rules of any stock exchange. 

6.    Representations and Warranties. 

6.1    Representations and Warranties of Mayne Pharma. The Mayne Pharma Companies hereby jointly and severally
represent and warrant to HPPI as of the date hereof as follows: 
 (a)    Organization; Authorization;
Enforceability. Each Mayne Pharma Company is a company duly organized, validly existing and in good standing under the laws of Australia. Each Mayne Pharma Company has the full right, company power, and authority to enter into this Agreement and
the other Transaction Documents to which it is a party and to consummate the transactions contemplated hereby and thereby and otherwise to carry out its obligations hereunder and thereunder. With respect to each Mayne Pharma Company, the execution,
delivery and performance of this Agreement and the other Transaction Documents to which it is a party and 

  
 5 

 
the performance by each such Mayne Pharma Company of the transactions contemplated by hereby and thereby have been duly authorized by all necessary company action on the part of such Mayne Pharma
Company. With respect to each Mayne Pharma Company, each of this Agreement and the other Transaction Documents to which it is a party has been duly executed by such Mayne Pharma Company, and when delivered by such Mayne Pharma Company in accordance
with the terms hereof, will constitute the valid and legally binding obligation of such Mayne Pharma Company, enforceable against it in accordance with its terms. 

(b)    No Conflicts. The execution, delivery and performance by each Mayne Pharma Company of this Agreement and
the other Transaction Documents to which it is a party and the consummation by such Mayne Pharma Company of the transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of such Mayne Pharma
Company’s organizational or charter documents or (ii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any governmental authority to which such Mayne Pharma
Company is subject or by which any property or asset of such Mayne Pharma Company is bound or affected. 

(c)    Litigation. There is no action, pending or, to the knowledge of each Mayne Pharma Company, threatened in
writing against such Mayne Pharma Company which, individually or in the aggregate, challenges the legality, validity or enforceability of this Agreement or any of the other Transaction Documents to which it is a party. 

6.2    Representations and Warranties of HPPI. HPPI hereby represents and warrants to Mayne Pharma as of the date
hereof as follows: 
 (a)    Organization; Authorization; Enforceability. HPPI is a corporation duly
incorporated, validly existing and in good standing under the laws of the State of Delaware. HPPI has the requisite corporate power and authority to enter into this Agreement and the other Transaction Documents and to consummate the transactions
contemplated hereby and thereby and otherwise to carry out its obligations hereunder and thereunder. The execution, delivery and performance of this Agreement and the other Transaction Documents and the performance by HPPI of the transactions
contemplated by hereby and thereby have been duly authorized by all necessary corporate action on the part of HPPI. Each of this Agreement and the other Transaction Documents has been duly executed by HPPI, and when delivered by HPPI in accordance
with the terms hereof, will constitute the valid and legally binding obligation of HPPI, enforceable against it in accordance with its terms. 

(b)    No Conflicts. The execution, delivery and performance by HPPI of this Agreement and the other Transaction
Documents to which it is a party and the consummation by HPPI of the transactions contemplated hereby and thereby do not and will not: (i) conflict with or violate any provision of HPPI’s certificate of incorporation, bylaws or other
organizational or charter documents or (ii) conflict with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any governmental authority to which HPPI is subject or by which any
property or asset of HPPI is bound or affected. 
 (c)    Litigation. There is no action, pending or, to the
knowledge of HPPI, threatened in writing against HPPI which, individually or in the aggregate, challenges the legality, validity or enforceability of this Agreement or any of the other Transaction Documents. 

  
 6 

 7.    Miscellaneous. 

7.1    Fees and Expenses. Except as expressly set forth in the Transaction Documents, each party hereto shall pay
the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. 

7.2    Entire Agreement. This Agreement, together with the exhibits hereto, and the other Transaction Documents,
together with the annexes, exhibits and schedules thereto, contain the entire understanding of the parties hereto with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with
respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules. 

7.3    Amendments; Waivers. No provision of this Agreement may be waived, modified, supplemented or amended except
in a written instrument signed, in the case of an amendment, by the duly authorized representatives of HPPI and Mayne Pharma or, in the case of a waiver, by the duly authorized representative of the party hereto against whom enforcement of any such
waived provision is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party hereto to exercise any right hereunder in any manner impair the exercise of any such right. 

7.4    Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall
not be deemed to limit or affect any of the provisions hereof. 
 7.5    Successors and Assigns. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their successors and permitted assigns. No party hereto may assign this Agreement or any rights or obligations hereunder without the prior written consent of the other parties
hereto. 
 7.6    No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto
and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person. 

7.7    Governing Law. This Agreement and any dispute arising hereunder shall be governed by and construed and
enforced in accordance with the laws of the State of Delaware applicable to agreements made and to be performed wholly within such State, without regard to its conflict of law rules that would result in the application of the laws of another
jurisdiction. 
 7.8    Counterparts; Execution. This Agreement may be executed in two or more counterparts, all
of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party hereto and delivered to each other party hereto, it being understood that the parties hereto need
not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or “.pdf” signature page were an original thereof. The words “execute,”
“execution,” “signed,” “signature,” and words of like import in or related to any document to be signed in 

  
 7 

 
connection with this Agreement and the transactions contemplated hereby (other than any stock certificates or the warrants) shall be deemed to include electronic signatures, each of which shall
be of the same legal effect, validity and enforceability as a manually executed signature, to the extent and as provided for in any applicable law. 

7.9    Severability. If any term, provision, covenant or restriction of this Agreement or any of the Transaction
Documents is held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be
affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable. 
 7.10    Remedies. In addition to being entitled to exercise all
rights provided herein or granted by law, including recovery of damages, each party hereto shall be entitled to specific performance under this Agreement and the transactions contemplated hereby. Each party hereto agrees that monetary damages may
not be adequate compensation for any loss incurred by reason of any breach of obligations contained in this Agreement and hereby agree to waive and not to assert in any action for specific performance of any such obligation the defense that a remedy
at law would be adequate. 
 7.11    Dispute Resolution. In the event of any action, question or disagreement
arising from or relating to this Agreement, the parties hereto agree to settle such action, question or disagreement by arbitration before three arbitrators in New York, New York, selected by, and such arbitration to be administered by, the American
Arbitration Association (“AAA”) in accordance with its Commercial Arbitration Rules, and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction thereof. Each of the parties hereto agrees and
acknowledges that all actions, questions or disagreements between or among them arising from or relating to this Agreement are subject to the alternative dispute resolution procedures of this Section 7.11. Each of the parties hereto agrees that
any aspect of alternative dispute resolution not specifically covered in this Agreement shall be covered, without limitation, by the applicable AAA rules and procedures. Each of the parties hereto further agrees that any determination by the
arbitrator regarding any action, question or disagreement arising from or relating to this Agreement shall be final and binding upon the parties hereto and shall not be subject to further appeal. 

[Signature page follows] 

  
 8 

 IN WITNESS WHEREOF, HPPI, Mayne Pharma and Mayne Pharma International have duly
executed this Agreement as of the date first written above. 
  

					
	HEDGEPATH PHARMACEUTICALS, INC.
		
	By:	 	/s/ Nicholas J. Virca
		 	Name:	 	Nicholas J. Virca
		 	Title:	 	President and CEO

 
					
	
	MAYNE PHARMA VENTURES PTY LTD
		
	By:	 	/s/ Nick Freeman
		 	Name:	 	Nick Freeman
		 	Title:	 	Authorized Signatory

 
					
	
	MAYNE PHARMA INTERNATIONAL PTY LTD

 
					
		
	By:	 	/s/ Nick Freeman
		 	Name:	 	Nick Freeman
		 	Title:	 	Authorized Signatory

  
 A-1 

 EXHIBIT A 

FORM OF THIRD AMENDED AND RESTATED SUPPLY AND LICENSE AGREEMENT 

  
 A-2 

 EXHIBIT B 

FORM OF AMENDED AND RESTATED SUBLICENSE AGREEMENT 

  
 B-1 

 EXHIBIT C 

FORM OF RESTATED SERIES B CERTIFICATE OF DESIGNATION 

  
 C-1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]